FDA Rejects Summit’s Ivonescimab Application, Shares Fall
The regulator cited a lack of statistically significant overall survival benefit, while investors await data from a separate first-line lung cancer trial.
Makkler Newsroom · Nov 16, 06:53 PM · 1 min read
